Recursion Pharmaceuticals raises $2.15M

What does Recursion Pharmaceuticals do?
Recursion Pharmaceuticals, is a company which is combining machine learning, bioinformatics and experimental biology for identifying 100 new treatments in 10 years for many of the shelved assets and drugs. Their initial focus is on the orphan disease, by their main technology has great applications in infectious disease, oncology and inflammation. Thier system will enable them in bringing their partner’s shelved assets to markets for new indications at very low price on the dollar compared to the regular drug discovery approaches. The company has the potential of radically accelerating drug discovery. This is a biotechnology revolution, where drug discovery can occur ten times cheaper and faster than before.
How much Recursion Pharmaceuticals was funded?
The company raised $2.15M in Series A on November 22, 2016 from AME Cloud Ventures, EPIC Ventures, Data Collective Obvious Ventures, Felicis Ventures and Lux Capital.
Previous funding
$12.9M in Series A on October 3, 2016 from Wild Basin Investments, Data Collective, AME Cloud Ventures, EPIC Ventures, Lux Capital and Obvious Ventures.
$130k on January 1, 2014
$170k on August 15, 2014
$830k on February 23, 2015
$1.5M on February 25, 2015 from National Institutes of Health
$2.65M on December 4, 2015
What is next for Recursion Pharmaceuticals?
Recursion Pharmaceuticals plans on using the latest funding raised for development of its “Platform 2.0”, an innovative merge of AI and biology. This platform will help in the discovery of drugs for any disease which can be modeled in human cells at a fast rate. Apart from its disruptive platform, the company’s early focus is on drug re-purposing which makes it possible to cheaply and rapidly translate discoveries into the clinic. Its business strategy and technology are making this company attractive to big pharmaceutical partners, attested to by their current partnerships.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals was founded on November 5, 2013 by Chris Gibson, Dean Li and Blake Borgeson. It has its headquarters in Salt Lake City, UT.